Rimonabant-some of the benefits
Written by admin on Sunday, March 23rd, 2008 in rimonabant study.
Rimonabant has been sold in Europe under the brand name Acomplia since 2006.Unlike other diet drugs, which may stop being effective after only a few months, Rimonabant is having lasting effects. The reason for that Rimonabant is so effective is the fact that this drug work on a different system in the body than previous diet pills. Dr. Xavier Pi-Sunyer of St. Luke’s Roosevelt Medical Center in New York City led an investigation of Rimonabant that followed subjects over a period of two years.
This specialist declared the following: “This is a very interesting diet pill that works in a different way that what we knew untill now. It’s very promising and more than that,because we allready have proves that shows that to us.” Dr. Pi-Sunyear’s reserche found that patiens who were treated with Rimonabant lost weight more then any other diet pills and were able to keep it off for two years. The first in a new class of drugs known as CB-1 receptors, Rimonabant is an appetite suppressant that stops chemical messages of hunger from getting through to the brain. The result is not only weight loss but also better regulation of sugar and fat metabolism.
Another benefit outcome of clinical trials of Acomplia is that the drug also appears to reduce cravings for nicotine. According to a trial study reported by the North American Association for the Study of Obesity (NAASO), smokers who took Rimonabant were twice as likely to quit. Further, there was no weight gain associated with quitting, which is often a concern for smokers, especially if they are already overweight. So,the conclusion is that Rimonabant can be used also as a pill for helping people quit smoking.
In another study, this one a joint effort of NAASO and the American Diabetes Association, 38% of the patiens in a group randomized to receive 20 mg of Rimonabant daily stopped smoking after 10 weeks. The subjects who stopped smoking gained an average of only 0,5 pounds. This was in contrast to the fact that only 16% of subjects in a placebo group stopped smoking after 10 weeks. Those in the placebo group who did stop smoking gained an average of 6 pounds. Althought Rimonabant has not officially been approved for use as a smoking cessation aid, its effects on smoking are quite encouraging.
Besides this two big benefits Acomplia helps people with other problems and diseases such as diabeatis,cardiovascular risks and the newest one is resistens to alcohol fat building effect in the liver.
Alcoholic fatty liver is a cause for more serious disease, and alcoholism is a leading cause of liver disease in the U.S. and other countries.
“Clinical trials testing the effectiveness of CB1 receptor blockers in the treatment of both alcoholic and nonalcoholic fatty liver and their more severe sequelae may be warranted,” the researchers concluded.
